David B. Yaden
@ExistWell
Associate Professor at @HopkinsMedicine; PhD; Science of psychedelics and other altered states of consciousness @TheYadenLab @JHPsychedelics @psychedelethics
Is the psychedelic hype bubble about to burst? Might that be best for the field? In a new @JAMAPsych article w/ me, @jpotash1, & R. Griffiths, we argue for moving beyond overly negative AND positive extremes to embrace the actual evidence @JHPsychedelics jamanetwork.com/journals/jamap…
Easily one of the best conferences I have attended so far! @GordonConf Shout out to the leadership of @kwanalexc @VVyazovskiy @MelissaHerman4 @ViditaVaidya This experience had so many highlights (but apparently, I can only post 4 pictures in one post). #GRCPsychedelics
CPCR faculty David Yaden (@existwell) presented and participated in a panel on The Evolving Theory for Explaining Psychedelic Drug Action with Mark Geyer, Harriet de Wit, Franz Vollenweider, Bryan Roth, and Scott Thompson at #GRCPsychedelics
Good morning! An excellent panel today on the evolving theory for explaining psychedelic drug action #GRCPsychedelics
We worked so well as a team for the #GRCPsychedelics @VVyazovskiy @MelissaHerman4 @ViditaVaidya and congrats to @TheBorisLab and @MikaelPalner, who will be the future vice-chairs!
Great panel this morning on the human and clinical studies of psychedelics - my impression is we have come a long way in the last few years in terms of design and quantification #GRCPsychedelics
With @CaleighPropes, @MariannaGrazz, Kyle Patch & @ExistWell, we reviewed ICDs from psilocybin clinical trials across the U.S., and provided a systematic qualitative description of these ICDs.
New paper thread! 🧵 Many have called for “enhanced” informed consent documents (ICD) for psychedelic research & treatments, with growing calls for tailored ICDs in the psychedelic bioethics lit. But how closely do ICDs in psychedelic clinical trials reflect these proposals?
Amazing pre-clinical poster session at #GRCPsychedelics. Play the "Where's Waldo" of @JHPsychedelics postdocs and faculty. 5 is the number to beat.
Poster session in full swing. Lots of exciting unpublished work. #GRCPsychedelics
Good morning! An excellent panel today on the evolving theory for explaining psychedelic drug action #GRCPsychedelics
It’s high time the field of psychedelic research move beyond the mystical experience construct (MEQ). While many critiques of the measure rest on misconceptions, persistent misunderstandings & psychometric limitations lead us to recommend transcending it.
Thrilled to connect at the Neurobiology of Psychedelics Gordon Research Conference (@GordonConf) next week! CPCR researchers and fellow scientists will discuss wide range of topics, including preclinical and clinical research, drug discovery, and neuroplasticity.
so interesting but correct to point out dosages. they call “low dose” 5mg/kg, yet that’s higher than pretty much any behavioral mouse studies and roughly equivalent to the highest dose we ever give humans. their regular 15mg/kg dose is way higher than we ever give humans.
1/🚨 Interesting and surprising animal data was just published in @Nature_NPJ on psilocybin’s geroprotective (lifespan extension) potential 🍄 → +51% increase in fibroblast lifespan (in vitro) → Monthly "low-dose" psilocybin (5–15 mg/kg) doubled survival in aged mice →…
also featuring posters from @winstonian3 and Nate Heller @JHPsychedelics !
Thrilled to connect at the Neurobiology of Psychedelics Gordon Research Conference (@GordonConf) next week! CPCR researchers and fellow scientists will discuss wide range of topics, including preclinical and clinical research, drug discovery, and neuroplasticity.
Excited for this conference!!!! #GRCPsychedelics If you are coming, please drop by the poster and say hi. Also looking forward to hosting the Trainee Mixer on Monday with Lindsay. We have some amazing things in store waiting for all the trainees!
Thrilled to connect at the Neurobiology of Psychedelics Gordon Research Conference (@GordonConf) next week! CPCR researchers and fellow scientists will discuss wide range of topics, including preclinical and clinical research, drug discovery, and neuroplasticity.
As the field progresses, we argue that psychedelic research can work towards improving its rigor and transparency by adopting Open Science practices, as well as learning from methods that have been applied in other settings (e.g. in industry-sponsored trials) to mitigate bias.
We’re excited to welcome Lucy Frith, Brian D. Earp & Arianne Shahvisi as our new joint EiCs! As leading experts in #bioethics & #medicalethics, their collective leadership promises to shape the journal’s future with intellectual rigor, inclusivity & innovation. Learn more about…
📚✨ ~500 Papers. ~30 Researchers & Experts. One Annotated Psychedelics Bibliography... Introducing the 2024 edition of Psychedelic Alpha's Interdisciplinary Annotated Psychedelic Research Bibliography, by @MichaelHaichin. psychedelicalpha.com/news/the-inter…
New publication, in press 🚨Psychedelics Beyond Medicine: Treatment, Enhancement, Hype, Consent, and the Limits of Medicalization - led by @Katherine_Chg, Mina Caraccio, Sebastian Porsdam Mann, with @ExistWell @psychedelethics and others in @JournalPHP researchgate.net/publication/39…
Curious about psychedelic therapy? Join CPCR Associate Director, Dr. Albert Garcia-Romeu for the American Psychological Associations @APA Psychedelics: From Research to Clinical Practice training on Sept 13. Open to clinicians, researchers, and anyone eager to understand this…